Literature DB >> 24035070

The use of octreotide to manage symptoms of bronchorrhea: a case report.

Meera Pahuja1, Ray W Shepherd2, Laurel J Lyckholm3.   

Abstract

Octreotide, a synthetic analogue of the hormone somatostatin, is primarily used in palliative medicine because of its antisecretory effect and has been shown to be effective in the management of bowel obstruction, nausea, and diarrhea. Octreotide also has been successfully used for the management of bronchorrhea in both inpatient and outpatient settings. We report the case of a 47-year-old female with a history of bronchioloalveolar cell carcinoma whose copious bronchial secretions were controlled with octreotide. Octreotide should be further evaluated as a first-line treatment for bronchorrhea. Published by Elsevier Inc.

Entities:  

Keywords:  Bronchorrhea; bronchioloalveolar carcinoma; octreotide

Mesh:

Substances:

Year:  2013        PMID: 24035070      PMCID: PMC4343310          DOI: 10.1016/j.jpainsymman.2013.06.008

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  21 in total

Review 1.  Octreotide for malignant bowel obstruction: twenty years after.

Authors:  Sebastiano Mercadante; Giampiero Porzio
Journal:  Crit Rev Oncol Hematol       Date:  2012-01-25       Impact factor: 6.312

2.  Successful treatment of bronchorrhea with octreotide in a patient with adenocarcinoma of the lung.

Authors:  Emma Hudson; Jason F Lester; Richard L Attanoos; Seamus J Linnane; Anthony Byrne
Journal:  J Pain Symptom Manage       Date:  2006-09       Impact factor: 3.612

Review 3.  Systematic review of strategies to measure HIV-related diarrhea.

Authors:  Jill Tinmouth; Gabor Kandel; George Tomlinson; Sharon Walmsley; Hillary A Steinhart; Richard Glazier
Journal:  HIV Clin Trials       Date:  2007 May-Jun

4.  Biochemistry and rheology of sputum in asthma.

Authors:  E E Keal
Journal:  Postgrad Med J       Date:  1971-03       Impact factor: 2.401

5.  Effects of treatment with somatostatin analogues on QT interval duration in acromegalic patients.

Authors:  Letizia Maria Fatti; Massimo Scacchi; Elisabetta Lavezzi; Francesca Pecori Giraldi; Martina De Martin; Paola Toja; Georgios Michailidis; Marco Stramba-Badiale; Francesco Cavagnini
Journal:  Clin Endocrinol (Oxf)       Date:  2006-11       Impact factor: 3.478

6.  Successful treatment of refractory bronchorrhea by inhaled indomethacin in two patients with bronchioloalveolar carcinoma.

Authors:  S Homma; M Kawabata; K Kishi; E Tsuboi; K Narui; T Nakatani; K Nakata
Journal:  Chest       Date:  1999-05       Impact factor: 9.410

7.  Expression of MUC5AC and MUC5B mucins in normal and cystic fibrosis lung.

Authors:  D A Groneberg; P R Eynott; T Oates; S Lim; R Wu; I Carlstedt; A G Nicholson; K F Chung
Journal:  Respir Med       Date:  2002-02       Impact factor: 3.415

8.  Epidermal growth factor system regulates mucin production in airways.

Authors:  K Takeyama; K Dabbagh; H M Lee; C Agustí; J A Lausier; I F Ueki; K M Grattan; J A Nadel
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

Review 9.  Bronchio-alveolar carcinoma. A clinical overview and bibliography.

Authors:  F Edgerton; U Rao; H Takita; R G Vincent
Journal:  Oncology       Date:  1981       Impact factor: 2.935

Review 10.  Role of epidermal growth factor receptor activation in regulating mucin synthesis.

Authors:  J A Nadel
Journal:  Respir Res       Date:  2001-02-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.